vadadustat Report issue

Small molecule Experimental
AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW
  • Now
Vadadustat is an experimental medication which acts as a HIF prolyl-hydroxylase inhibitor and thereby increases endogenous production of erythropoietin, which stimulates production of hemoglobin and red blood cells. It is in Phase III clinical trials for the treatment of anemia caused by chronic kidney disease.   Wikipedia

Chemistry

  • SMILES: OC(=O)CNC(=O)c1ncc(cc1O)c2cccc(Cl)c2
  • InChIKey: JGRXMPYUTJLTKT-UHFFFAOYSA-N
  • Mol. Mass: 306.71
  • ALogP: 1.92
  • ChEMBL Molecule:
    vadadustat  
More Chemistry

Pharmacology

Alternative names

akb-6548 | pg-1016548 | vadadustat

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Anemia (Phase 3)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 3)

Coronavirus Infections (Phase 2)

Drug Interactions (Phase 1)

Hamartoma (Phase 3)

Healthy Volunteers (Phase 3)

Kidney Diseases (Phase 2)

Kidney Failure, Chronic (Phase 2)

Liver Diseases (Phase 1)

Pharmacokinetics (Phase 1)

Renal Insufficiency, Chronic (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 37
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue